Covid-19 Task Force: Archipelago Vaccines Developed in America & Trials in Indonesia

Merdeka.com – Spokesperson for the Covid-19 Task Force, Wiku Bakti Bawono Adisasmito, said the Nusantara vaccine, the idea of ​​former Health Minister (Menkes) Terawan Agus Putranto, was developed in the United States.

“The Nusantara vaccine is a type of vaccine developed in America and tested in Indonesia,” he said in a press conference broadcast via YouTube, BNPB Indonesia, Thursday (15/4).

Wiku hopes that the Nusantara vaccine development team will immediately coordinate with the Food and Drug Administration (BPOM) to resolve a number of issues related to phase one clinical trials. According to BPOM findings, there were a number of problems in the phase one clinical trial of the Nusantara vaccine.

Among other things, the manufacture of Nusantara vaccines is not sterile. In addition, the data on the safety of Nusantara vaccines were replaced by researchers and it was found that adverse events were found in 20 of the 28 study subjects.

“It is hoped that the Nusantara vaccine development team can coordinate well with BPOM so that the existing issues related to this vaccine can be resolved immediately,” he said.

Wiku added, in principle, the government supports the development of the Covid-19 vaccine. With a note, this development meets the criteria for making vaccines.

“In principle, all vaccines that will be given to the public must obtain permission from the BPOM, especially the aspects of safety, efficacy and feasibility. As long as they meet the criteria, the government will provide support, “he said.

DPR members and national figures participate in the Nusantara vaccine vaccination process at the Gatot Soebroto Army Hospital, Wednesday (14/4). The first process today is to take a blood sample from the vaccine recipient.

DPR members who participated were Deputy Chairman of the DPR, Sufmi Dasco Ahmad, Deputy Chairperson of Commission IX Melki Laka Lena, as well as members of the Indonesian Parliament from the PDI-P Faction, Adian Napitupulu. Meanwhile, a former Commander in Chief was also present TNI Gatot Nurmantyo.

Deputy Speaker of the DPR, Sufmi Dasco Ahmad, said that today’s vaccination agenda is to collect blood samples. The sample will be processed and used as a vaccine which will be inserted in the next seven days.

“Today I have taken a blood sample to be processed for 7 days to be used as an Nusantara vaccine which will then be inserted into my body in the next 7 days,” said Dasco at the Gatot Soebroto Army Hospital. (mdk/ray)

Also read:
Nusantara Vaccine Researchers: We are audited and supervised according to standards
Researchers Explain that Nusantara Vaccines Need Blood Samples of Recipients
Findings of the BPOM of the Nusantara Vaccine are not sterile, the task force must comply with WHO standards
Data of Phase 1 Clinical Studies of Nusantara Vaccines: 71.4% of Subjects Experiencing Unwanted Events
BPOM Findings: Researchers Replace Nusantara Vaccine Safety Data

– .